The Effect of L-Carnitine on Wound Healing in Patients With Diabetic Foot Ulcer.
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age30-75
SponsorAin Shams University
About this trial
Primary outcome: To evaluate the efficacy of L-Carnitine supplementation on length and depth ulcer size
Secondary outcome: To investigate the effect of L-Carnitine supplements on:
1. Vascular endothelial growth factor (VEGF) 2. Inflammatory markers TNF-a (Tumor necrosis factor alpha). 3. Hemoglobin A1C (HbA1c) And Lipid profile (cholesterol, triglycerides, high-density Lipoprotein (HDL) and low-density lipoprotein (LDL)). 4. To assess the type and likelihood of any adverse drug reaction that can be related to L-Carnitine supplementation. 5. QOL (DIABETES 39)
Eligibility criteria
Qualifiers
Adult Male or Female patients with diabetic neuropathy mean age (30-75) years old.
Having Diabetic neuropathy and Diabetic foot ulcer grade 1-2 (mild- moderate) according to Wagner classification.
Uncontrolled diabetic patients (HbA1c). < 9 duration of diabetic (5 - 10) years.
All patient treated with stable dose of anti-diabetic medication priors and during the period of the study.
Disqualifiers
Patients with other causes of ulcers.
Patient taking any antioxidant supplements including vitamin E, ascorbic acid, omega 3 fatty acid, Coenzyme Q10 within three months prior to enrollment in the study.
Patient with autoimmune disease.
Patient with liver disease or kidney disease.
Trial design
Treatments tested in this trial
- L- carnitine
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov